Video

EGFR-Resistant Disease in Lung Cancer

Related Videos
Marco Davila, MD, PhD
Ewa Kalinka, MD, PhD
Benjamin P. Levy, MD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Sandip P. Patel, MD
Tom van Meerten, MD, PhD, hematologist, Department of Hematology, University Medical Center Groningen
Andrew Ip, MD
Alec Watson, MD
Related Content
Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

FDA
January 16th 2025

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

Suresh Senan, MRCP, FRCR, PhD
January 15th 2025

Durvalumab Shifts Decades-Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC

NSCLC | © catalin | stock.adobe.com
January 14th 2025

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC